"Finally, decisions by countries like China to cut pollution in megacities after years of choking smog could provide a further push for electric vehicles of all types--from bicycles to commercial trucks. This increased demand also pushes down the cost of batteries, which benefits the industry as a whole."
"Ultimately, ABB's predictions are just that--predictions.
But when you see where we were with electric vehicles just three or four years ago, and see where we've got today, it isn't hard to imagine the pace of change being equally impressive over the coming years--maybe we really have hit the tipping point for electric cars."
"ABB quotes a comment by Volkswagen that predicts electric vehicles would be cheaper to make than internal combustion ones in just three years. This, presumably, is based on the premise that batteries and batteries alone are the component preventing electric cars from costing very little to make."
Google title if interested.
Google article title if interested, " Cancer Immunotherapy Named Breakthrough of the Year"
The plane, the plane. LOL :-)
KEYW Holding receives $115 mln contract for airborne collection services (KEYW) : Co announce that it has received a contract for continued overseas airborne collection services. The total value of the contract is $115 million and includes a base period of performance with three option periods through September 2016. Of this, $54 million is funded for collection services through March 2015.
Here comes BMY with a NEW pile of cash burning a hole in it;s pocket.
Dec 19, 2013 4:09 PM ET
Bristol-Myers Squibb Co. (BMY) will quit the diabetes-treatment business, selling its stake in a venture to partner AstraZeneca Plc (AZN) for as much as $4.3 billion to focus on cancer treatments.
AstraZeneca will pay $2.7 billion upfront and as much as $1.4 billion more depending on regulatory, commercial and sales goals, the companies said today. London-based AstraZeneca also will pay as much as $225 million if some assets are transferred to Bristol-Myers. Future royalty payments may add to the deal’s value.
Bristol-Myers will give up its share of new treatments such as Onglyza and Forxiga to AstraZeneca. While the companies expanded their alliance last year with the $5.3 billion purchase of Amylin Pharmaceuticals Inc., Bristol-Myers said the venture isn’t profitable and the New York-based drugmaker sees more promise in cancer, antiviral and specialty medicines.
“We think the deal makes a lot of strategic sense,” said Mark Schoenebaum, an analyst with International Strategy & Investment Group LLC. “The company is becoming more of a biotech company,” he said in a note to clients today.
Google article title if interested, "Piper Jaffray Initiates Coverage on Neurocrine Biosciences (NBIX)"
Stock analysts at Piper Jaffray started coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX) in a report issued on Thursday, Stock Ratings Network reports. The firm set an “overweight” rating and a $17.00 price target on the stock. Piper Jaffray’s price objective points to a potential upside of 84.38% from the company’s current price.
Wow, you're not very well informed, go look into Chipotle positioning with regard to, "Pizzeria Locale" and you might have something more intelligent to type. You really should consider medication, or a mutual fund. LOL :-)
YES!!! More validation we have a winning concept, and maybe an interested acquisition/roll up partner.
The company launched Pizzeria Locale in Denver in May with two partners and is exploring options for two more stores in the city, it said. Like Chipotle, Pizzeria Locale lets customers customize their meals. With a bake time of less than two minutes, the pies are ready more quickly than it takes to bake a standard frozen pizza.
"Opening Pizzeria Locale using a model similar to Chipotle allows us to make extraordinary pizza, made with high-quality ingredients accessible to everyone," Steve Ells, founder, chairman and co-CEO of Chipotle, said in a release.
Agreed, weird!! Deal with Sanofi and no press???
On December 16, 2013, Immunogen, Inc. (Nasdaq: IMGN) entered into a license agreement with sanofi-aventis U.S. LLC (NYSE: SNY) granting Sanofi rights to use our maytansinoid-based antibody-drug conjugate (ADC) technology to develop and commercialize products directed to a specific antigen target on an exclusive basis. Sanofi took this development and commercialization license pursuant to the terms of an existing right-to-test agreement entered into by the Company and Sanofi in 2006, and it is the first such license taken under that agreement.
In accordance with the terms of the right-to-test agreement, execution of the license agreement entitles us to receive an exercise fee of $2,000,000. We are also entitled to receive up to a total of $30,000,000 in development and regulatory milestone payments under the license agreement, as well as royalties on the commercial sales of any resulting products.
Too funny, see what you mean, BUT can't be remember, in addition to the three laws of robotics, we know have Googles, "Do No Evil" to guide our robots actions. :-)
"The robotics industry is in the early stages of a transformation from a primarily industrial market to a dynamic technology sector," he says. "This is an exciting industry with a bright future."
Google article title if interested, "IRobot CEO: Google may have bought Boston Dynamics for robotic package delivery"
Too Funny!! Go Colin :-)
""By the time that Google is delivering packages to the door, we would hope to be in millions of homes answering the door," he said."
iRobot upgraded to Strong Buy from Market Perform at Raymond James
Raymond James upgraded iRobot two notches to Strong Buy based on the new Roomba 800 and sales momentum expectations, and margin improvement from incremental Braava sales. Price target is $39.